Knowthestock.com
CLDX - Celldex Therapeutics Inc.

Sell

Weak GrowthEarnings/Profit is Negative
WeakStrong
WeakStrong

24%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 24.49%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative but improving
Net Margin is -2366.07%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 21.67
Debt Ratio is 0.05
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Negative
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Celldex Therapeutics Inc. (CLDX) - http://www.celldex.com/
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
Exchange - NASDAQ
Industry - Research and Development in Biotechnology (except Nanobiotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Anthony Marucci
Employees - 163
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.